Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL 3. August 2020 Thill M., Zahn M.-O., Welt A., Stickeler E., Nusch A., Fietz T., Rauh J., Wetzel N., Kruggel L., Jänicke M., Marschner N., Harbeck N., Wöckel A., Decker T., OPAL Registergruppe Cancer Res (2021) 81 (4_Supplement): PS11-16. Abstract Download REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. HemaSphere 4(S1) (EP1245), 583. Weiterlesen Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study. Link, H.,, Illerhaus, G., Martens, U. M., Salar, A., Depenbusch, R., Köhler, A., Engelhardt, M., Mahlmann, S., Zaiss, M., Lammerich, A., Bias P., Buchner, A. Weiterlesen